Get bonus pills when buying Cardizem ONLINE

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–July 2, 2003
Biovail Corporation (NYSE, TSX: BVF) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) fo…

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–April 2, 2003
Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched Cardizem(R) LA in the U.S. Launch elements include physician detailing, sampling, marketing and promotional activities. Biovail, in conjunction with the Company’s co-promotion partner Reliant Pharmaceuticals LLP, has approximately 800 sales representatives that…

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–April 29, 2003
— CardizemLA Prescriptions Exceed 20,000
— Retail Pharmacy Stocking Reaches 80%
— Managed Care Negotiations Cover 90% of U.S. Lives
Biovail Corporation (NYSE:BVF)(TSX:BVF) reported today on the progress of Cardizem(R)LA (diltiazem HCl), the recently launched once-daily controlled release medication for the treatment of hyperte…

TORONTO, ONTARIO, Apr 29, 2003 (CCNMatthews via COMTEX)
— CardizemLA Prescriptions Exceed 20,000
— Retail Pharmacy Stocking Reaches 80%
— Managed Care Negotiations Cover 90% of U.S. Lives

Most Popular
The Art Of Public Speaking: Build Connection With Your Audience
10 Jobs That Pay $30 An Hour
Public S…

CHICAGO, ILLINOIS, Mar 30, 2003 (CCNMatthews via COMTEX)
Presentation at American College of Cardiology Shows New Formulation Doubles Morning Exercise Tolerance, a Key Angina Measure
Nighttime dosing of a newly approved bl…

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–May 7, 2003
Biovail Corporation (NYSE:BVF) (TSX:BVF) announced today that it has achieved favorable formulary coverage for recently launched Cardizem(R) LA, a graded once-daily controlled release medication for t…

By Julius A. Karash, The Kansas City Star, Mo. Knight Ridder/Tribune Business News
Feb. 19–Aventis Pharmaceuticals and Andrx Corp. have agreed to pay a combined $80 million to settle claims of conspiring to keep a generic form of Cardizem CD off the market.
The money is earmarked for consumers, state agencies and insuran…

Business & Health/Medical Editors
TORONTO–(BW HealthWire)–July 24, 2001
Biovail Corporation (NYSE:BVF)(TSE:BVF)
– Combination of unique Cardizem(r) XL delivery profile and nighttime dosing
demonstrates clinically significant improvement over placebo and morning dosing

– Innovative formulation addresses circadian variation in blood pressure with
optima…

WASHINGTON, Oct. 21 /U.S. Newswire/ — The deadline to file claims
in the Cardizem(r) CD antitrust case has been extended through Nov.
15, 2003. Although tens of thousands of claims have already been
made, the deadline has been extended to give consumers more time to
act on their legal rights.

Most Popular
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
Pu…

TORONTO — Biovail Corporation (NYSE, TSX: BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has reached a settlement agreement with Watson Pharmaceuticals, Inc. (NYSE: WPI), with respect to patent litigation against Watso…